Inhibition of HIV fusion with multivalent gold nanoparticles. - Wikidata - awgldk - TriplyDB

Inhibition of HIV fusion with multivalent gold nanoparticles.

Inhibition of HIV fusion with multivalent gold nanoparticles.

http://www.wikidata.org/entity/Q42000178

about

Gold nanoprobes for theranostics Nanostructures for the Inhibition of Viral Infections The Quest for Anti-inflammatory and Anti-infective Biomaterials in Clinical Translation Gold compounds as therapeutic agents for human diseases Progress in antiretroviral drug delivery using nanotechnology A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application.Gold nanoparticles in biology and medicine: recent advances and prospects.Epidemic modeling with discrete-space scheduled walkers: extensions and research opportunities.Fast, high-yield synthesis of amphiphilic Ag nanoclusters and the sensing of Hg(2+) in environmental samples.Dendronized Anionic Gold Nanoparticles: Synthesis, Characterization, and Antiviral Activity.Gold nanoparticles for biology and medicine.Engineering nanomaterial surfaces for biomedical applications Gold nanoparticles for nucleic acid delivery.Multifunctional nanoparticles as simulants for a gravimetric immunoassay.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs Chitosan gel containing polymeric nanocapsules: a new formulation for vaginal drug delivery.Illuminating epidermal growth factor receptor densities on filopodia through plasmon coupling.Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles.Enhanced chiral recognition by cyclodextrin dimers.The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies.Nanoparticle-based drug delivery to the vagina: a review.Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection.Enhanced cellulose degradation using cellulase-nanosphere complexes.Size- and time-dependent alteration in metabolic activities of human hepatic cytochrome P450 isozymes by gold nanoparticles via microsomal coincubations Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.Pharmaceutical approaches to eradication of persistent HIV infection.Ligand-modulated interactions between charged monolayer-protected Au144(SR)60 gold nanoparticles in physiological saline.Translational challenges in targeting latent HIV infection and the CNS reservoir problem.Identification of toxin inhibitors using a magnetic nanosensor-based assay.Inorganic-organic hybrid nanomaterials for therapeutic and diagnostic imaging applications.More effective nanomedicines through particle design Gold nanoparticles to improve HIV drug delivery.Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future Nanotechnology and the treatment of HIV infection.Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation.Aspheric Solute Ions Modulate Gold Nanoparticle Interactions in an Aqueous Solution: An Optimal Way To Reversibly Concentrate Functionalized Nanoparticles Size-dependent antimicrobial properties of sugar-encapsulated gold nanoparticles synthesized by a green method Synthesis, characterization, and direct intracellular imaging of ultrasmall and uniform glutathione-coated gold nanoparticles

P2860

Q24629197-446B34B8-4227-4F85-8996-A6404AD4F415 Q26801513-5B3B981B-343F-4F1E-8116-800A3A448F51 Q28072029-296B006F-B554-40D7-B920-E151FA2041EF Q28243207-70B71739-EA76-454C-A133-A139238D8898 Q30395011-0CF94DBE-4FFD-463B-A6D2-12F921B03A1B Q30431343-E166BC86-AACD-4E5E-B6DF-26004CC97009 Q30452438-B91BF694-3467-41C8-87E5-9132AADCB92D Q30467305-907C107E-B057-42B2-A562-A088945AC66D Q30892324-D55DB827-652A-4F03-BB01-33DF109E2E18 Q30936781-601E806D-271D-4606-9456-8E9AA22CCB6B Q31045563-CBC75C90-A545-4801-B7C9-4A4757CBF872 Q33558781-1DD2C369-CCF0-4695-9BB0-CFC4B6CFB4A2 Q33680071-0330C332-F30D-43BD-9822-E462F916E881 Q33724219-030106FD-B90F-48E2-9F1F-CD6FA30A9A86 Q33756379-F16E3A65-E387-4AA8-8EB1-BAFBFA6E6070 Q33819656-11E835C6-E829-4510-B689-652B81075803 Q33829799-5DC8C8FB-BFCD-49CD-B7A3-C4BC5A3E6CFF Q33857681-3999E004-5519-4BED-BC07-68B3ED204808 Q33962349-2F9F3D02-9DED-4BB6-8C5A-14E026835563 Q33985752-C85FAEAB-2671-42A9-8F3F-AC00E85C9FB7 Q33993730-4CC43E33-C244-465E-81A3-DD9311F3243F Q34072375-A7DF2FA7-B90B-4D11-9A60-0229F25FA879 Q34079533-C04B47AE-F000-4393-A51C-7F14FB4D1391 Q34304758-F2F9DD20-C125-4465-9AA0-DA5F8E35666F Q34369266-B3686B82-754E-491D-A177-09DB6835D15C Q34702776-133E2009-27C2-4B8C-B60E-05365982645F Q34801630-81835ACE-8CE5-47A6-A7CD-892CA2B0E14C Q34941973-8A4161FF-34F6-4DC7-9589-C2E572078368 Q35001962-70F0CBEB-A2B1-4D6C-B62C-E6635D4E23C0 Q35009744-F443CE90-14AE-4596-9C20-291B762B9C2B Q35067034-54C12554-8CF6-49CD-9879-DBDE1D99D4FC Q35091821-C2A7EF12-BCD9-4628-AE70-A908C1462989 Q35106115-7A6CA89D-AEC9-4E62-BC74-FCE798809B57 Q35847982-FCC7CB7E-CE51-4F62-9FE5-AE54D489762F Q35942437-1F341188-A015-4689-9E7C-C5690058B0E1 Q35943647-AC901E28-5EB7-4CBB-A41C-CCECF3523D9F Q36132897-1E7E3F8B-C8A1-4BEE-9CFF-905CDC6D3912 Q36385181-18E88123-0B60-437C-B257-A8FC9326E3E1 Q36499202-047DF4B8-F62C-429F-839F-E091A557C4BE Q37025215-FD4F5792-2C80-4148-853A-A0A650CEE005

P2860

Inhibition of HIV fusion with multivalent gold nanoparticles.

http://www.wikidata.org/entity/Q42000178

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Inhibition of HIV fusion with multivalent gold nanoparticles.

@en

Inhibition of HIV fusion with multivalent gold nanoparticles.

@nl

type

label

Inhibition of HIV fusion with multivalent gold nanoparticles.

@en

Inhibition of HIV fusion with multivalent gold nanoparticles.

@nl

prefLabel

Inhibition of HIV fusion with multivalent gold nanoparticles.

@en

Inhibition of HIV fusion with multivalent gold nanoparticles.

@nl

P1433

Q42000178-3BB32FB7-6C12-4BF1-B5FA-BDE89FD78026

P1476

Q42000178-A5478CF6-1DBA-4FA2-97CB-3FA71D8B8561

P2093

Q42000178-0982F347-BD34-45CF-9339-EDB60E6AEC53

Q42000178-A9AD5EF0-72FE-40EA-9F3F-1FF0C055F869

Q42000178-C8E46908-C36C-43E1-A80B-519E3EAD5261

Q42000178-DBDDC9F5-18E3-4D83-B427-AE149EE0B57F

Q42000178-E3D4495C-A694-437E-874E-84EF1FD65808

P2860

Q42000178-29B87FC6-67EE-4151-B141-6CF7B7AB290D

Q42000178-2D16ED52-488A-4B7A-A609-EE93DB6B89BF

Q42000178-3550EB85-5580-43ED-AB48-5577EE154EEA

Q42000178-6EE12AE8-2D5F-41CA-9FA6-DDDEF4CD9CB3

Q42000178-908BD02E-7852-4D8E-A965-782EB1091137

Q42000178-B6937B2D-6D95-4F98-9BF9-A213118982C4

Q42000178-B814846E-A134-4FB5-A1F1-0C3D8BEC4782

Q42000178-BA8D6ACC-5854-4DAF-ACB3-30677EE19112

Q42000178-C6C0F243-0C99-4AFF-9926-4844E040917B

Q42000178-D35D7727-E90A-4103-92B5-7DEEF0AB699F

P304

Q42000178-5A5D1521-6D07-4016-976B-4B873B3AB347

P31

Q42000178-460DA9E1-5B8A-4735-8F6A-1A053C9A1BE5

P356

Q42000178-5DD3C9BB-5211-4952-8BAB-BBDF7FD71A69

P407

Q42000178-C42B50D0-3971-4F3C-A40A-3C8A07737BAF

P433

Q42000178-F657D92B-A3A5-4C15-9ECD-7AA385E51441

P478

Q42000178-ECAFDA10-F259-424B-89A3-DE62A3BB15C1

P50

Q42000178-B3489B0D-1E45-401F-B350-5B6460B9C8BA

P577

Q42000178-A6AF66A6-4F2E-494C-8BF4-8A4A66803993

P5875

Q42000178-885911DF-88CC-4026-A6F4-0C98A3A50C20

P698

Q42000178-BAC1AAC4-35CB-4DF3-BE90-448CEA505886

P921

Q42000178-C8AAC695-200F-4AFF-B062-B57CB2D8219F

P932

Q42000178-943C9945-E6BE-460C-BC8E-09F4D25FB522

P356

P1433

Journal of the American Chemical Society

P1476

Inhibition of HIV fusion with multivalent gold nanoparticles.

@en

P2093

Christian Melander

http://www.w3.org/2001/XMLSchema#string

Christopher J Ackerson

http://www.w3.org/2001/XMLSchema#string

Daniel L Feldheim

http://www.w3.org/2001/XMLSchema#string

Mary-Catherine Bowman

http://www.w3.org/2001/XMLSchema#string

T Eric Ballard

http://www.w3.org/2001/XMLSchema#string

P2860

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

Antibody neutralization and escape by HIV-1

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.

Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.

Nanotechnological applications in medicine.

A thermodynamic investigation into the binding properties of DNA functionalized gold nanoparticle probes and molecular fluorophore probes.

An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.

Structure of a thiol monolayer-protected gold nanoparticle at 1.1 A resolution.

P304

6896-6897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JA710321G

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

David M. Margolis

P577

2008-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5379120

http://www.w3.org/2001/XMLSchema#string

P698

18473457

http://www.w3.org/2001/XMLSchema#string

P921

P932

2916654

http://www.w3.org/2001/XMLSchema#string